Dark

Check out our Level2View

ABMD
Abiomed Inc
stock NASDAQ

Inactive

Dec 21, 2022

381.02USD+0.060%(+0.23)20,612,257

Pre-market

0.00USD-100.000%(-380.79)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 14, 2022

07:00AM EST Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification Business Wire

Jan 12, 2022

08:04AM EST Abiomed Reports Results Of First-In-Huma Early Feasability Study Of Co.'s preCARDIA System Benzinga

Jan 10, 2022

08:20AM EST Abiomed Announces Regulators In Japan And Hong Kong Approve Impella 5.5 With SmartAssist; FDA Grants Impella BTR Conditional IDE Approval For First-In-Human Early Feasibility Study Benzinga

Jan 7, 2022

01:04PM EST Morgan Stanley Maintains Underweight on Abiomed, Raises Price Target to $292 Benzinga

Dec 29, 2021

07:00AM EST Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Nov 18, 2021

07:00AM EST Abiomed to Present at Upcoming Investor Conferences Business Wire

Nov 4, 2021

08:23AM EDT Abiomed Highlights Review Of Impella Heart Pump Studies At Transcatheter Cardiovascular Therapeutics (TCT) 2021 Benzinga

Nov 1, 2021

08:00AM EDT Data On Use Of Abiomed's Pumps To Be Showcased At Transcatheter Cardiovascular Therapeutics (TCT) 2021 Nov. 4-5 Benzinga

Oct 28, 2021

07:52AM EDT Abiomed Inc. (ABMD) announced a profit for second quarter that declined from the same period last year. RTTNews

07:50AM EDT Abiomed Lowers FY22 Sales Guidance From $1.03B-$1.05B To $1.01B-$1.03B Vs. $1.04B Est. Benzinga

07:48AM EDT Abiomed Q2 EPS $1.03 Beats $0.97 Estimate, Sales $248.10M Beat $247.66M Estimate Benzinga

07:07AM EDT Abiomed Q2 Net Income $57.0 Mln Or $1.24/shr Vs. $62.2 Mln Or $1.36/shr Last Year RTTNews

07:01AM EDT Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year Business Wire

04:08AM EDT Earnings Scheduled For October 28, 2021 Benzinga

Oct 27, 2021

11:55AM EDT Abiomed's Earnings Outlook Benzinga

Oct 7, 2021

07:00AM EDT Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification Business Wire

Aug 18, 2021

11:04AM EDT Smallest Heart Pump From Abiomed Gets FDA Breakthrough Device Tag Benzinga

08:08AM EDT Abiomed : FDA Grants Breakthrough Device Designation To Impella ECP, Smallest Heart Pump RTTNews

08:05AM EDT Abiomed Says FDA Grants Breakthrough Device Designation To Co's Impella Benzinga

08:02AM EDT FDA Grants Breakthrough Device Designation to Impella ECP, the World's Smallest Heart Pump Business Wire

Aug 6, 2021

05:53AM EDT SVB Leerink Maintains Market Perform on Abiomed, Raises Price Target to $375 Benzinga

Aug 4, 2021

05:38PM EDT Abiomed Raises FY22 Sales Guidance From $990M-$1.03B To $1.03B-$1.05B vs $1.02B Estimate Benzinga

05:38PM EDT Abiomed Q1 Adj. EPS $1.10 Beats $1.05 Estimate, Sales $252.60M Beat $240.91M Estimate Benzinga

04:23PM EDT Abiomed Q1 Loss/share $0.59 Vs. Profit $0.98 Year Ago RTTNews

04:15PM EDT Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year Business Wire

Jul 20, 2021

12:07PM EDT SVB Leerink Maintains Market Perform on Abiomed, Lowers Price Target to $335 Benzinga

Jul 15, 2021

07:00AM EDT Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification Business Wire

Jun 29, 2021

08:24AM EDT Abiomed Inc. (ABMD), on Tuesday, announced that its newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration pre-market approval or PMA as safe and effective to treat acute right heart failure for up to 14 days. RTTNews

08:08AM EDT Abiomed: Impella RP With SmartAssist Gets FDA Pre-market Approval To Treat Acute Right Heart Failure RTTNews

08:07AM EDT Abiomed Receives FDA Pre-Market Approval For Impella RP With SmartAssist Benzinga

08:03AM EDT FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure Business Wire

Jun 18, 2021

12:47PM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021 Benzinga

07:45AM EDT Deutsche Bank Initiates Coverage On Abiomed with Buy Rating, Announces Price Target of $360 Benzinga

Jun 1, 2021

09:10AM EDT Abiomed (ABMD) said it has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed's product portfolio to expand options for patients with acute decompensated heart failure or ADHF. RTTNews

08:19AM EDT CORRECTION: Abiomed Ticker Is 'ABMD' Benzinga

08:19AM EDT Abiomed Acquires preCARDIA; Terms Not Disclosed Benzinga

08:06AM EDT Abiomed Acquires PreCARDIA To Expand Options For Patients With acute Decompensated Heart Failure RTTNews

08:03AM EDT Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients Business Wire

May 25, 2021

07:00AM EDT Abiomed to Present at Upcoming Investor Conferences Business Wire

May 6, 2021

11:10AM EDT Raymond James Highlights Earlier ClinicalTrials.gov Record For Boston Scientific's Vortex Circulatory Support System; Notes Successful Commercialization Of Product Would Open Existing ~$900M Market; Sees Vortex As Competition For Abiomed's Impella Benzinga

Apr 29, 2021

01:24PM EDT Abiomed Earlier Issued FY22 Guidance; Sees Sales $990M-$1.03B vs $998.13M Est. Benzinga

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

07:17AM EDT Abiomed Inc. (ABMD) announced a profit for its fourth quarter that climbed from the same period last year. RTTNews

07:13AM EDT Abiomed Q4 EPS $1.24 Beats $1.10 Estimate, Sales $241.25M Beat $230.38M Estimate Benzinga

07:13AM EDT Abiomed Q4 EPS $1.24 Vs $0.70 Last Year RTTNews

07:01AM EDT Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin Business Wire

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 28, 2021

03:57PM EDT Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella Business Wire

08:12AM EDT Abiomed Appoints Paula Johnson To Board RTTNews

08:03AM EDT Dr. Paula A. Johnson Joins Abiomed Board of Directors Business Wire

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 15, 2021

08:13AM EDT Abiomed Announces First Patient Enrolled In PROTECT IV Randomized Controlled Trial Of Impella Benzinga

08:08AM EDT Abiomed Says First Patient Enrolled In PROTECT IV Randomized Controlled Trial Of Impella RTTNews

08:03AM EDT First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella Business Wire

Apr 8, 2021

07:00AM EDT Abiomed Fourth Quarter Fiscal 2021 Earnings and Conference Call Notification Business Wire

Mar 4, 2021

09:00AM EST MEDCERT Enables the Use of the Single Access Procedure with Impella CP Introducer Sheaths in Europe Business Wire

Feb 17, 2021

08:05AM EST Abiomed Appoints Myron Rolle To Board RTTNews

08:03AM EST Abiomed Announces Appointment of Dr. Myron Rolle to Board of Directors Business Wire

07:00AM EST Abiomed to Present at Upcoming Investor Conferences Business Wire

Jan 29, 2021

09:44AM EST Morgan Stanley Maintains Underweight on Abiomed, Raises Price Target to $245 Benzinga

09:39AM EST SVB Leerink Maintains Market Perform on Abiomed, Raises Price Target to $375 Benzinga

09:05AM EST Abiomed Highlights Presentation Of Study Of Impella 5.5 With SmartAssist Benzinga

09:03AM EST Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist Business Wire

07:45AM EST The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga

Jan 28, 2021

08:20AM EST Abiomed: Q3 Earnings Insights Benzinga

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

07:21AM EST Abiomed Inc. (ABMD) released earnings for third quarter that declined from the same period last year. RTTNews

07:06AM EST Abiomed Q3 EPS $1.35 Beats $1.13 Estimate, Sales $231.70M Beat $225.59M Estimate Benzinga

07:04AM EST Abiomed Q3 GAAP Net Income $61.9 Mln Or $1.35/Shr Vs $69.2 Mln Or $1.51/Shr Last Year RTTNews

07:00AM EST Abiomed Announces Q3 FY 2021 Record Revenue of $232 Million, up 5% Year Over Year, With 31% Operating Margin Business Wire

04:08AM EST Earnings Scheduled For January 28, 2021 Benzinga

Jan 23, 2021

09:14AM EST The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 14, 2021

07:00AM EST Abiomed Third Quarter Fiscal 2021 Earnings and Conference Call Notification Business Wire

Jan 7, 2021

08:10AM EST Abiomed HIghlights Surpassing Of Over 1,000 Patents Benzinga

08:06AM EST Abiomed Says Surpassed More Than 1,000 Patents Worldwide RTTNews

08:03AM EST Abiomed Continues to Strengthen its Intellectual Property, Now Holds More Than 1,000 Patents Business Wire

Jan 5, 2021

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

Dec 30, 2020

08:16AM EST The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga

Dec 29, 2020

07:00AM EST Abiomed to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 21, 2020

08:11AM EST Abiomed Says First Two Patients In The World Treated With Abiomed Breethe OXY-1 System RTTNews

08:05AM EST First Patients, Including a COVID-19 Patient, Treated with Abiomed's Innovative ECMO Technology Business Wire

Dec 15, 2020

11:11AM EST Morgan Stanley Maintains Underweight on Abiomed, Raises Price Target to $238 Benzinga

08:08AM EST Abiomed Announces Impella Has Completed First Stage Of FDA Early Feasibility Study And FDA Has Granted 510(k) Clearance To Impella XR Sheath Benzinga

08:07AM EST Abiomed Announces Achievement Of Two Milestones In Development Of Small Bore Access For Impella Heart Pump RTTNews

08:03AM EST Two Milestones Achieved Toward Small Bore Access with Impella Business Wire

Nov 25, 2020

07:00AM EST Abiomed to Hold Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire

Nov 11, 2020

07:00AM EST Abiomed to Hold Fireside Chat at the Stephens Annual Investment Conference 2020 Business Wire

Nov 5, 2020

08:24AM EST Abiomed: 1K Patients Treated With Impella 5.5 With SmartAssist Heart Pump RTTNews

08:19AM EST First 1,000 Patients Treated With Impella 5.5 With SmartAssist, A Heart Pump Designed For Surgeons Benzinga

Oct 29, 2020

07:58AM EDT Abiomed Inc. (ABMD) released a profit for its second quarter that rose from last year. RTTNews

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

07:15AM EDT Abiomed Q2 EPS $1.36 Beats $0.92 Estimate, Sales $209.76M Beat $198.93M Estimate Benzinga

07:11AM EDT Abiomed Q2 Revenue Up 2% To $209.8 Mln RTTNews

07:00AM EDT Abiomed Announces Q2 FY 2021 Revenue of $210 Million, Up 27% Over Q1 FY 2021 and Up 2% Over Q2 FY 2020 With 29.2% Operating Margin Business Wire

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 28, 2020

08:11AM EDT First Patients Treated With The World's Smallest Heart Pump, The 9Fr Impella ECP Benzinga

Oct 26, 2020

08:17AM EDT Abiomed Inc. (ABMD) said Monday that the United States Food and Drug Administration has approved the Abiomed Breethe OXY-1 System, an all-in-one compact cardiopulmonary bypass system. RTTNews

07:59AM EDT Abiomed Says FDA Grants 510(k) Clearance For Abiomed Breethe OXY-1 System RTTNews

07:56AM EDT FDA Grants 510(k) Clearance For Abiomed's Cardiopulmonary Support Technology Benzinga

07:55AM EDT FDA Grants 510(k) Clearance for Abiomed's Innovative Cardiopulmonary Support Technology Business Wire

Oct 16, 2020

08:05AM EDT Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP Business Wire

07:08AM EDT Abiomed Highlights Presentation Of Data At TCT Connect Showing Higher Survival With Impella Pre-PCI Benzinga

07:05AM EDT Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women Business Wire

Oct 15, 2020

08:30AM EDT Abiomed to Host a Virtual Meeting to Discuss New Clinical Data Presented at TCT Connect Business Wire

08:10AM EDT Abiomed Announces New Contemporary PROTECT III Study Data RTTNews

08:05AM EDT Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization with Impella Leads to Improved Outcomes Business Wire

Oct 14, 2020

08:15AM EDT Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves Left Ventricular Ejection Fraction Benzinga

Oct 12, 2020

10:17AM EDT SVB Leerink Maintains Market Perform on Abiomed, Lowers Price Target to $280 Benzinga

Oct 8, 2020

05:00PM EDT Abiomed Second Quarter Fiscal 2021 Earnings and Conference Call Notification Business Wire

08:00AM EDT TCT Connect to Highlight How Impella Enables Improved Outcomes for High-Risk PCI, Cardiogenic Shock and Right Heart Failure Patients Business Wire

Sep 30, 2020

04:01PM EDT Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors GlobeNewswire Inc

Sep 14, 2020

07:00AM EDT Abiomed to Hold Fireside Chat at the Raymond James North American Equities Conference Business Wire

Sep 8, 2020

07:00AM EDT Abiomed to Hold Fireside Chat at the 18th Annual Morgan Stanley Global Healthcare Conference Business Wire

Aug 7, 2020

09:14AM EDT Morgan Stanley Maintains Underweight on Abiomed, Raises Price Target to $217 Benzinga

05:37AM EDT SVB Leerink Maintains Market Perform on Abiomed, Raises Price Target to $335 Benzinga

Aug 6, 2020

09:40AM EDT Abiomed shares are trading higher after the company reported better-than-expected Q1 EPS and impella sales results. UPDATE: Shares have since reversed. Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:21AM EDT Abiomed Inc. (ABMD) announced a profit for first quarter that decreased from last year. RTTNews

07:10AM EDT Abiomed Q1 Adj. EPS $0.59 Beats $0.29 Estimate, Impella Sales $155.40M Beat $151.11M Estimate Benzinga

07:04AM EDT Abiomed Q1 Net Income $44.6 Mln Or $0.98/shr Vs. $88.9 Mln Or $1.93/shr Last Year RTTNews

07:00AM EDT Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin Business Wire

Aug 4, 2020

07:22AM EDT FDA Issues Emergency Use Authorization For Impella Heart Pumps To Provide Unloading Therapy To COVID-19 Patients; Impella Is Manufactured By Abiomed Benzinga

07:00AM EDT FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients Business Wire

Jul 30, 2020

08:00AM EDT Large Multi-Center Study in Japan Finds High Survival Rates with Use of Impella Heart Pump Business Wire

Jul 16, 2020

07:44AM EDT Abiomed: FDA Approves Data Streaming From Impella Console RTTNews

07:08AM EDT FDA Approves One-way Digital Data Streaming During Patient support From Abiomed's Automated Impella Controller RTTNews

07:02AM EDT Abiomed Announces FDA Approval Of Data Streaming From Co.'s Automated Impella Controller Benzinga

07:00AM EDT FDA Approves Data Streaming from the Impella Console, Setting the Stage for Artificial Intelligence Algorithms to Further Improve Patient Outcomes Business Wire

07:00AM EDT Abiomed First Quarter Fiscal 2021 Earnings and Conference Call Notification Business Wire

Share